NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $4.55 +0.11 (+2.48%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$4.52 -0.03 (-0.66%) As of 10/2/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aquestive Therapeutics Stock (NASDAQ:AQST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$4.43▼$4.5950-Day Range$3.60▼$5.3952-Week Range$2.93▼$7.55Volume2.27 million shsAverage Volume2.24 million shsMarket Capitalization$571.07 millionP/E RatioN/ADividend YieldN/APrice Target$9.17Consensus RatingModerate Buy Company Overview Aquestive Therapeutics, Inc. is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations. Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders. The company is also developing Anaphylm, an epinephrine sublingual film intended to address severe allergic reactions, along with other products and product candidates. The company was formerly known as MonoSol Rx and adopted the Aquestive Therapeutics name in 2018. Headquartered in Warren, New Jersey, Aquestive serves the U.S. market and works with commercial and development partners to support the availability of its products in international markets. Its leadership team is headed by Chief Executive Officer Daniel Barber.AI Generated. May Contain Errors. Read More Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreAQST MarketRank™: Aquestive Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 654th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAquestive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAquestive Therapeutics has a consensus price target of $9.17, representing about 101.5% upside from its current price of $4.55.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Aquestive Therapeutics are expected to remain at ($0.50) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.22% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 11.81, which indicates bearish sentiment.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 6.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.51 News SentimentAquestive Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aquestive Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $166,175.00 in company stock.Percentage Held by Insiders6.81% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by Institutions32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQST Stock News HeadlinesAquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Consensus Target Price of $9.17 According to AnalystsOctober 2 at 2:15 AM | americanbankingnews.comAquestive Therapeutics: The Market Is Already Pricing In Anaphylam's SuccessSeptember 30, 2026 | seekingalpha.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 4 at 1:00 AM | Profits Run (Ad)Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard DalySeptember 29, 2026 | globenewswire.comComparing Aquestive Therapeutics (NASDAQ:AQST) & Oculis (NASDAQ:OCS)September 29, 2026 | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Agilent (A) and Aquestive Therapeutics (AQST)September 18, 2026 | theglobeandmail.comInsider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $120,500.00 in StockSeptember 17, 2026 | insidertrades.comInsider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells 8,750 SharesSeptember 12, 2026 | insidertrades.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $6.46 at the start of the year. Since then, AQST shares have decreased by 29.6% and is now trading at $4.55. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.08. The business earned $13.82 million during the quarter, compared to analysts' expectations of $11.42 million. Read the conference call transcript. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $68 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,500,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE). Company Calendar Last Earnings8/11/2026Today10/04/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AQST's financial health is in the Green zone, according to TradeSmith. AQST has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees147Year Founded2004Price Target and Rating Average Price Target for Aquestive Therapeutics$9.17 High Price Target$12.00 Low Price Target$6.00 Potential Upside/Downside+101.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.78 million Net Margins-144.63% Pretax Margin-144.63% Return on EquityN/A Return on Assets-52.40% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio6.74 Sales & Book Value Annual Sales$44.54 million Price / Sales12.82 Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-16.25Miscellaneous Outstanding Shares125,510,000Free Float116,965,000Market Cap$571.07 million OptionableOptionable Beta1.49 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:AQST) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
